Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ziv Carmel, M.D.
- Phone Number: +972-9-7478570
- Email: zivca@clalit.org.il
Study Locations
-
-
-
Hod-HaSharon, Israel, 45100
- Recruiting
- Shalvata Mental Health Center
-
Contact:
- Ziv Carmel, M.D
- Phone Number: +972-9-7478570
- Email: zivca@clalit.org.il
-
Principal Investigator:
- Ziv Carmel, M.D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and Female, aged 21-70 years, who meet DSM-IV TR diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study.
Exclusion Criteria:
- History of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to DSM-IV TR criteria.
- Hamilton depression scale rated 25 and above (moderate to severe depression)
- Current alcohol or other substance abuse or dependence
- Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
- History of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery.
- Severe somatic co-morbidity
- History of seizures Cardiac pace maker or other electronic implants Pregnancy and lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ziv Carmel, M.D, Shalvata MHC affiliated to Tel-Aviv universtiy, Sackler school of medicine
- Principal Investigator: Abraham Zangen, Ph.D., Weizmann Institute, Rehovot, Israel
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SH 30107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.